Inhibition of constitutive activation of STAT3 by curcurbitacin-I (JSI-124) sensitized human B-Leukemia cells to apoptosis

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3302-3314

  Ishdorj, Ganchimeg ^a,b   Johnston, James B ^a,b   Gibson, Spencer B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CUCURBITACIN; CUCURBITACIN I; DEATH RECEPTOR 4; JSI 124; SERINE; STAT3 PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE 1; HUMANS; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHOSERINE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRITERPENES; UP-REGULATION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 78650488834     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0550     Document Type: Article

References (48)

1. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19(21):2496-504.
2. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009;9(11):798-809.
3. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
4. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 1997;100(12):3140-8.
5. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: Implication for apoptosis resistance. Leukemia 2005; 19(4):513-23.
6. Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model. Immunol Cell Biol 2008;86(6):506-14.
7. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005;16(6):601-7.
8. Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: Ancient compound shedding new light on cancer treatment. Scientific World Journal 2010;10:413-8.
9. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003;63(6):1270-9.
10. Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, et al. Chronic lymphocytic leukemia. Hematology 2002;193-213.
11. Faderl S, Ferrajoli A, Frankfurt O, Pettitt A. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: Experience with single-agent and combination therapy. Leukemia 2009; 23(3):457-66.
12. Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, et al. Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. J Biol Chem 2008;283(24):16818-29.
13. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009;324(5935):1713-6.
14. Montero JA, Hurlé JM. Sculpturing digit shape by cell death. Apoptosis 2010;15(3):365-75.
15. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998;273:7787-90.
16. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999;18:5242-51.
17. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: Targeting and activation of death receptors. Cytokine Growth Factor Rev 2005;16:55-76.
18. Nagane M, Huang HJ, Cavenee WK. The potential of TRAIL for cancer chemotherapy. Apoptosis 2001;6(3):191-7.
19. Tanaka F, Kawakami A, Tamai M, Nakamura H, Iwanaga N, Izumi Y, et al. IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximidesensitive mechanism: Novel finding of cycloheximide-regulating death receptor expression. Int J Mol Med 2005;15(5):833-9.
20. Sarcar B, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase. Virology 2004;322(1):51-60.
21. Murray PJ. The JAK-STAT signaling pathway: Input and output integration. J Immunol 2007;178(5):2623-9.
22. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 2010;115(14):2852-63.
23. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-10.
24. Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM, et al. Src family kinase activity is required for signal transducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchoragedependent and -independent growth of human tumor cells. Mol Cancer Ther 2003;2:461-9.
25. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65.
26. Aziz MH, Hafeez BB, Sand JM, Pierce DB, Aziz SW, Dreckschmidt NE, et al. Protein kinase cvarepsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 2010;29 (21):3100-9.
27. Galdiero M, Vitiello M, D'Isanto M, Raieta K, Galdiero E. STAT1 and STAT3 phosphorylation by porins are independent of JAKs but are dependent on MAPK pathway and plays a role in U937 cells production of interleukin-6. Cytokine 2006;36(5-6):218-28.
28. Abe K, Hirai M, Mizuno K, Higashi N, Sekimoto T, Miki T, et al. The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway. Oncogene 2001;20:3464-74.
29. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997;17: 6508-16.
30. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Mculler-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374(Pt 1):1-20.
31. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
32. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
33. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109 (6):2293-302.
34. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 2009;15(4):1250-8.
35. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez- Luna JL, et al. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002;21:7611-8.
36. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003;9:316-26.
37. Sano S, Chan KS, Kira M, Kataoka K, Takagi S, Tarutani M, et al. Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res 2005;65:5720-9.
38. Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, et al. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 2003;22(51):8356-69.
39. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2001;12:773-82.
40. Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 2007; 47:546-55.
41. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005;65:5054-62.
42. Ray S, Lee C, Hou T, Boldogh I, Brasier AR. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 2008;36(13):4510-20.
43. Ivanov SV, Salnikow K, Ivanova AV, Bai L, Lerman MI. Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene 2007;26(6):802-12.
44. Neufert C, Pickert G, Zheng Y, Wittkopf N, Warntjen M, Nikolaev A, et al. Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle 2010;9(4):652-5.
45. Shi X, ZhangH, Paddon H, LeeG,Cao X, Pelech S. Phosphorylation of STAT3 serine-727 by cyclin-dependent kinase 1 is critical for nocodazole-induced mitotic arrest. Biochemistry 2006;45(18): 5857-67.
46. Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 2010;70: 1356.
47. Lui VW, Yau DM, Wong EY, Ng YK, Lau CP, Ho Y, et al. Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 2009;30(12):2085-94.
48. Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, Chung JY, et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 2009;8(24):2386-95.